S Gastrointestinal And Liver Disease 12th Edition Jun 2026

Often referred to simply as Sleisenger and Fordtran’s , the 12th edition remains the definitive, encyclopedic reference for physicians, fellows, and residents in gastroenterology and hepatology. Published in 2020 by Elsevier, this two-volume set continues the legacy of providing comprehensive, evidence-based, and clinically actionable information on the entire spectrum of digestive disorders. The 12th edition arrives at a time of rapid advancements in gut microbiome research, immunotherapy for liver disease, and minimally invasive endoscopic techniques, all of which are thoroughly integrated into this update.

: Offers updated therapeutic algorithms for Inflammatory Bowel Disease (IBD), detailing the selection and sequencing of novel biologics, small molecules, and biosimilars. Core Section Breakdown

Fully searchable text across desktop and mobile devices for point-of-care reference.

Sleisenger and Fordtran's Gastrointestinal and Liver Disease s gastrointestinal and liver disease 12th edition

In an era where medical knowledge evolves at a breakneck pace, the 12th edition arrives as an essential update, bridging the gap between cutting-edge research and bedside practice. What’s New in the 12th Edition?

This textbook is aimed at:

This is for informational purposes only. For medical advice or diagnosis, consult a professional. AI responses may include mistakes. Learn more Share public link Often referred to simply as Sleisenger and Fordtran’s

The 12th edition is divided into several sections, including:

3. Columnar and Squamous Diseases of the Esophagus and Stomach

Sleisenger and Fordtran 12th edition release date, GI and liver disease textbook 2024, best gastroenterology textbook for boards, MASLD management textbook 2024, endoscopic submucosal dissection textbook. What’s New in the 12th Edition

A quick glance at the table of contents reveals the breathtaking scope of the 12th edition. The book is logically structured into major parts, including:

A new chapter dedicated to the role of the gut microbiome in health and disease, plus integrated discussions on fecal microbiota transplantation (FMT) for C. difficile and emerging microbiome-based therapies.